By

Luke Timmerman

21
Aug
2019

An Unforgettable Experience: The Kilimanjaro Climb to Fight Cancer Yearbook

The Kilimanjaro Climb to Fight Cancer was a marvelous experience. In every way. Weeks later, I’m still absorbing what it means to scientists at Fred Hutch, and to the biotech community. To start, consider the numbers: Our team of 27 climbers raised $1,587,475 for cancer research More than 2,200 donors contributed from around the country 33 sponsors supported the cause...
Read More
11
Jul
2019

Better Cancer Treatment Through Better Information: Cindy Perettie on The Long Run

Today’s guest on The Long Run is Cindy Perettie. Cindy is the CEO of Cambridge, Mass.-based Foundation Medicine. This company does genomic analysis on tumors. If you know more of this molecular nitty-gritty information – things like the underlying gene mutations that send cancer cells into out-of-control growth sprees – then you ought to occasionally come up with more effective...
Read More
2
Jul
2019

Cancer Survivor and Cancer Drug Developer: Laura Shawver on The Long Run

Today’s guest on The Long Run is Laura Shawver. Laura is the CEO of San Diego-based Synthorx. This company, based on research from The Scripps Research Institute, is using a couple of newly invented base pairs of DNA to make site-specific modifications on fully expressed proteins. This capability, Synthorx believes, could be put to practical use to craft ideal drug-like...
Read More
13
Jun
2019

Who Will Be the Next Celgene of Dealmaking?

Stars aligned beautifully, not long ago, for dealmaking at Celgene. The company, early this decade, was raking in the dough from the multiple myeloma drug Revlimid. Cash had to be spent somewhere. Celgene didn’t have much of its own R&D. Shareholders weren’t clamoring for their cut, via quarterly cash dividends. The stock soared, without any jet fueled-share buybacks. Letting cash...
Read More
13
Jun
2019

Predicting Who Will Benefit from Cancer Drugs: Liz O’Day on The Long Run

Today’s guest on The Long Run is Liz O’Day. Liz is the founder and CEO of Cambridge, Mass.-based Olaris Therapeutics. This is a scrappy little startup that’s studying metabolites that could provide clues for predicting which patients are most likely to respond to certain cancer drugs. Figuring out which patients are likely to respond is one of those perennial challenges...
Read More
1 2 3 24